TELA Bio
TELA
67 hedge funds and large institutions have $175M invested in TELA Bio in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
20% more call options, than puts
Call options by funds: $54K | Put options by funds: $45K
0% more funds holding
Funds holding: 67 → 67 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.98% less ownership
Funds ownership: 90.21% → 89.23% (-0.98%)
22% less capital invested
Capital invested by funds: $223M → $175M (-$48.6M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
Top Sellers
TELA Hedge Fund Activity: Q3 2023 in Review
67 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q3 2023, worth a combined $175M — down 22% from $223M a quarter earlier.
Fund positioning in TELA was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 29 added to existing stakes and 20 trimmed.
The largest buyer was First Light Asset Management, adding an estimated $7.01M. The largest seller was Opaleye Management, cutting an estimated $7.71M.
- 67 institutional investors held TELA Bio (TELA) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $175M of TELA Bio stock for Q3 2023, down 22% quarter-over-quarter.
- 3 funds opened new TELA Bio positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest TELA Bio buyer in Q3 2023 was First Light Asset Management, an estimated $7.01M added.
- The largest TELA Bio seller in Q3 2023 was Opaleye Management, an estimated $7.71M sold.
Based on aggregated 13F filings for Q3 2023.